Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions

Bibliography

• International Diabetes Federation. Diabetes Atlas, Third edition. 2007. IDF website. Available from: http://www.idf.org
   Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31:S55-60
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-1346
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
   PubMed Web of Science ®Google Scholar
• Gaede P, Lund-Andersen H, Parving HL, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
   PubMed Web of Science ®Google Scholar
• Stang MR, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999;22:925-7
   PubMed Web of Science ®Google Scholar
• Bertilson L, Dahl ML, Ingelman-Sundberg M, et al. Interindividual and interethnic differences in polymorphic drug oxidation:implications for drug therapy with focus on psychoactive drugs. In: Pacifici GM, Fracchia GN, editors, Advances in drug metabolism in man. Luxemburg, European Commision, 15439 EN, EC, DGXII-E-4, 1995. p. 85-196
   Google Scholar
• Holstein A, Stumvoll M. Contraindications can damage your health – is metformin a case in point? Diabetologia 2005;48:2454-9
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006: CD002967
   Google Scholar
• Bruijstens LA, van Luin M, Buscher-Jungerhans PP, Bosch FH. Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment. Neth J Med 2008;66:185-90
   PubMed Web of Science ®Google Scholar
• National Institue for Health and Clinical Excellence. Clinical guideline 66. The management of type 2 diabetes. May 2008:13-14. Available from: http://www.nice.org.uk/nicemedia/pdf/CG066NICEGuidelineCorrectedDec08
   Google Scholar
• UKPDS Group. Effect of intensive blood-glucose control with Metformin on complications in overweight patients with type 2 diabetes. United Kingdom Prospective Diabetes Study. Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications. Arch Intern Med 2008;168:2070-80
   PubMed Web of Science ®Google Scholar
• Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335:497-506
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-579
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Goodman A, Metformin Investigator Group. Efficacy of metformin in patients with non-insulin diabetes mellitus. N Engl J Med 1995;333:541-9
   PubMed Web of Science ®Google Scholar
• Goley A. Metformin and body weight. Int J Obes 2008;32:61-72
   Web of Science ®Google Scholar
• Douek IF, Allen SE, Ewings P, et al. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabet Med 2005;22:634-40
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Wilcock C, Scarpello JHB. Metformin and the intestine. Diabetologia 2008;51:1552-53
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71
   PubMed Web of Science ®Google Scholar
• Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005;20:379-86
   PubMedGoogle Scholar
• Zhang L, Dresser MJ, Gray AT, et al. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 1997;51:913-21
   PubMed Web of Science ®Google Scholar
• Fujita T, Urban TJ, Leabman MK, et al. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 2006;95:25-36
   PubMed Web of Science ®Google Scholar
• Takane H, Shikata E, Otsubo K, et al. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008;9:415-22
   PubMed Web of Science ®Google Scholar
• Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117:1422-31
   PubMed Web of Science ®Google Scholar
• Leabman MK, Huang CC, Kawamoto M, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002;12:395-405
   PubMedGoogle Scholar
• Wang ZJ, Yin O, Tomlinson B, Chow MSS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 2008;18:637-45
   PubMed Web of Science ®Google Scholar
• Glucophage Prescribing Information. Merck Serno; 2008
   Google Scholar
• FDA 2008. Metformin. Official FDA information, side effects and uses. Available from: http://www.drugs.com/pro/metformin.html
   Google Scholar
• Khamdang S, Takeda M, Noshiro R, et al. Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 2002;303:534-9
   PubMed Web of Science ®Google Scholar
• Alivanis P, Giannikouris I, Paliuras C, et al. Metformin-associated lactic acidosis treated with continous renal replacement therapy. Clin Ther 2006;28:396-400
   PubMed Web of Science ®Google Scholar
• Price G. Metformin lactic acidosis, acute renal failure and rofecoxib. BJA 2003;91:909-10
   Google Scholar
• Davidson JA, Scheen AJ, Howlett HC. Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus. Drug Saf 2004;27:1205-16
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulphonylurea plus pioglitazone versus a sulphonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141-7
   PubMed Web of Science ®Google Scholar
• Garber A, Klein E, Bruce S, et al. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2006;8:156-63
   PubMed Web of Science ®Google Scholar
• Home PD, Jones NP, Pocock SJ, et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007;24:626-34
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meininger G, Sheng D, et al; for the Sitagliptin 024 Study Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205
   PubMed Web of Science ®Google Scholar
• Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733-45
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43
   PubMed Web of Science ®Google Scholar
• Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-40
   PubMed Web of Science ®Google Scholar
• Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5
   PubMed Web of Science ®Google Scholar
• Precose Prescribing Information. Bayer Pharmaceuticals Corporation 2004
   Google Scholar
• Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 2005;28:601-31
   PubMed Web of Science ®Google Scholar
• Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008;25:435-41
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94
   PubMed Web of Science ®Google Scholar
• Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999;22:960-4
   PubMed Web of Science ®Google Scholar
• Costa B, Pinol C. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health care. Diabetes and Acarbose Research Group. Diabetes Res Clin Pract 1997;38:33-40
   PubMed Web of Science ®Google Scholar
• Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomised, placebo-controlled study. Diabet Med 1999;16:755-61
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin treated patients with type 2 diabetes. Diabetes Care 1998;21:2050-5
   PubMed Web of Science ®Google Scholar
• Phillips P, Karrasch J, Scott R, et al. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003;26:269-73
   PubMed Web of Science ®Google Scholar
• Halimi S, Le Berre MA, Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract 2000;50:49-56
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Ferreira Alves de Magalhaes C, Salvatore T, et al. Reduction of the acute bioavailability of metformin by the α-glucosidase inhibitor acarbose in normal man. Eur J Clin Invest 1994;24(Suppl 3):50-4
   PubMed Web of Science ®Google Scholar
• Gérard J, Lefèbvre PJ, Luyckx AS. Glibenclamide pharmacokinetics in acarbose treated type 2 diabetics. Eur J Clin Pharmacol 1984;27:233-6
   PubMed Web of Science ®Google Scholar
• Hiele M, Ghoos Y, Rutgeerts P, Vantrappen G. Effects of acarbose on starch hydrolysis. Study in healthy subjects, ileostomy patients, and in vitro. Dig Dis Sci 1992;37:1057-67
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Häring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002;34:217-24
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007;30:2148-53
   PubMed Web of Science ®Google Scholar
• Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-9
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 2007;46:1-12
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br J Clin Pharmacol 2008;65:78-86
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Thomas S, Bauer S, et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 2006;80:657-67
   PubMed Web of Science ®Google Scholar
• Tornio A, Niemi M, Neuvonen PJ, et al. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 2008;36:73-80
   PubMed Web of Science ®Google Scholar
• Budde K, Neumayer HH, Fritsche L, et al. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003;55:368-74
   PubMed Web of Science ®Google Scholar
• Deng LJ, Wang F, Li HD. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 2005;61:831-6
   PubMed Web of Science ®Google Scholar
• Jaakkola T, Backman JT, Neuvonen M, et al. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 2006;61:70-78
   PubMed Web of Science ®Google Scholar
• Kortboyer JM, Eckland D. Pioglitazone has low potential for drug interactions. Diabetologia 1999;42(Suppl 1):A228
   Google Scholar
• Jaakkola T, Laitila J, Neuvonen PJ, et al. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006;99:44-51
   PubMed Web of Science ®Google Scholar
• Park JY, Kim KA, Kang MH, et al. Effect of rifampicin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004;75:157-62
   PubMed Web of Science ®Google Scholar
• Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Ann Rev Physiol 1999;61:337-62
   PubMed Web of Science ®Google Scholar
• Holstein A, Plaschke A, Hammer C, et al. Characteristics and time course of severe glimepiride- versus glibenclamide induced hypoglycaemia. Eur J Clin Pharmacol 2003;59:91-7
   PubMed Web of Science ®Google Scholar
• Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes 2003;111:405-14
   PubMed Web of Science ®Google Scholar
• Rydberg T, Wählin-Boll E, Melander A. Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography. J Chromatogr 1991;564:223-233
   PubMed Web of Science ®Google Scholar
• Rydberg T, Jönsson A, Roder M, et al. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994;17:1026-30
   PubMed Web of Science ®Google Scholar
• Müller G, Hartz D, Pünter J, et al. Differential interaction of glimepiride and glibenclamide with the b-cell-sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1994;1191:267-77
   PubMed Web of Science ®Google Scholar
• Kramer W, Müller G, Geisen K. Characterization of the molecular mode of action of the Sulfonylurea, Glimepiride, at b-Cells. Horm Metab Res 1996;28:464-8
   PubMed Web of Science ®Google Scholar
• Overkamp D, Volk A, Maerker E, et al. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care 2002;25:2065-73
   PubMed Web of Science ®Google Scholar
• Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with Type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17:467-73
   PubMed Web of Science ®Google Scholar
• González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications 2008 [Epub ahead of print]
   PubMedGoogle Scholar
• Kirchheiner J, Bauer S, Meineke I, et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and on the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002;12:101-9
   PubMedGoogle Scholar
• Kirchheiner J, Brockmöller J, Meineke I, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002;71:286-96
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Terashita S, Kagayama A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica 2004;34:415-27
   PubMed Web of Science ®Google Scholar
• Appel S, Rufenacht T, Kalafsky G, et al. Lack of interaction between fluvastatin and oral hypoglycaemic agents in healthy subjects and in patients with non-insulindependent diabetes mellitus. Am J Cardiol 1995;76:29A-32A
   PubMed Web of Science ®Google Scholar
• Semple CG, Omile C, Buchanan KD, et al. Effect of oral verapamilon glibenclamide stimulated insulin secretion. Br J Clin Pharmacol 1986;22:187-90
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, et al. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001;69:400-6
   PubMed Web of Science ®Google Scholar
• Roberge RJ, Kaplan R, Frank R, et al. Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann Emerg Med 2000;36:160-3
   PubMed Web of Science ®Google Scholar
• Menzies DJ, Dorsainvil PA, Cunha BA, et al. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 2002;113:232-4
   PubMed Web of Science ®Google Scholar
• Lee K, Mize R, Lowenstein SR. Glyburide-induced hypoglycaemia and ranitidine. Ann Intern Med 1987;107:261-2
   PubMed Web of Science ®Google Scholar
• Kubacka RT, Antal EJ, Juhl RP. The paradoxical effect of cimetidine and ranitidine on glibenclamide pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1987;23:743-51
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, et al. Effect of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001;69:194-200
   PubMed Web of Science ®Google Scholar
• Niemi M, Kivisto KT, Backman JT, et al. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. Br J Clin Pharmacol 2000;50:591-5
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Niemi M, Fredrikson H, et al. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol 2007;63:732-40
   PubMed Web of Science ®Google Scholar
• Niemi M, Cascorbi I, Timm R, et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002;72:326-32
   PubMed Web of Science ®Google Scholar
• Wang R, Chen K, Wen SY, et al. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin Pharmacol Ther 2005;78:9092
   Google Scholar
• Suzuki K, Yanagawa T, Shibasaki T, et al. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract 2006;72:148-54
   PubMed Web of Science ®Google Scholar
• Holstein A, Plaschke A, Ptak M, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 2005;59:103-6
   Web of Science ®Google Scholar
• Becker ML, Visser LE, Trienekens PH, et al. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 2008;83:288-92
   PubMed Web of Science ®Google Scholar
• Zhang Y, Si D, Chen X, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br J Clin Pharmacol 2007;64:67-74
   PubMed Web of Science ®Google Scholar
• Sesti G, Laratta E, Cardellini M, et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metabol 2006;91:2334-9
   PubMed Web of Science ®Google Scholar
• Holstein A, Hahn M, Stumvoll M, Kovacs P. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycaemia in patients with type 2 diabetes. Horm Metab Res 2009; Feb12. [Epub ahead of print]
   PubMedGoogle Scholar
• Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas – A GoDARTs study. Diabetes 2007;56:2178-82
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• UKPDS Correspondence. Lancet 1998;352:1932-4
   PubMed Web of Science ®Google Scholar
• Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 2008;31:1672-8
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;358:1709-16
   PubMed Web of Science ®Google Scholar
• Mayer C, Holstein A, Stumvoll M. Oral antidiabetic agents: how much kidney disease can we tolerate? Exp Rev Endocrinol Metab 2007;2:469-75
   PubMedGoogle Scholar
• Black C, Donnelly P, Mcintyre L, et al. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;18:CD004654
   Google Scholar
• Novonorm Prescribing Information. Novo Nordisk Inc.; 2006
   Google Scholar
• Starlix Prescribing Information. Novartis; 2006
   Google Scholar
• Pacanowski MA, Hopley CW, Aquilante CL. Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. Expert Opin Drug Metab Toxicol 2008;4:529-44
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007;46:93-108
   PubMed Web of Science ®Google Scholar
• Niemi M, Leathart JB, Neuvonen PJ, et al. Polymorphism in CYP2C8 is associated with reduced plasma concentration of repaglinide. Clin Pharmacol Ther 2003;74:380-7
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Meineke I, Müller G, et al. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in healthy volunteers. Clin Pharmacokinet 2004;43:267-78
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Niemi M, Neuvonen M, et al. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005;78:388-99
   PubMed Web of Science ®Google Scholar
• Niemi M, Backmann JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially harzadous interaction between gemfibrozil and repaglinide. Diabetologia 2003;46:347-51
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Jaakkola T, Neuvonen PJ, et al. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol 2006;62:217-23
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Backman JT, Neuvonen M, et al. Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br J Clin Pharmacol 2004;58:390-6
   PubMed Web of Science ®Google Scholar
• Hatorp V, Hansen KT, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 2003;43:649-60
   PubMed Web of Science ®Google Scholar
• Niemi M, Neuvonen PJ, Kivistö KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. J Clin Pharmacol 2001;70:58-65
   Web of Science ®Google Scholar
• Busk Bidstrup T, Damkier P, Kristensen Olsen A, et al. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. Br J Clin Pharmacol 2006;61:49-57
   PubMed Web of Science ®Google Scholar
• Hirshberg Y, Karara AH, Pietri AO, et al. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 2000;23:349-53
   PubMed Web of Science ®Google Scholar
• Takanohashi T, Koizumi T, Mihara R, et al. Prediction of the metabolic interaction of nateglinide with other drugs based on in vitro studies. Drug Metab Pharmacokinet 2007;22:409-18
   PubMed Web of Science ®Google Scholar
• Anderson D, Shelley S, Crick N, et al. A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers. Int J Clin Pharmacol Ther 2002;42:457-64
   Google Scholar
• Anderson D, Shelley S, Crick N, et al. No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol 2002;42:1358-65
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Juntti-Patinen L, et al. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br J Clin Pharmacol 2005;60:208-17
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today 2007;43:13-25
   PubMed Web of Science ®Google Scholar
• Meier JJ. Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia 2008;51:703-13
   PubMed Web of Science ®Google Scholar
• Januvia Prescribing Information. Merck & Co., Inc. 2007
   Google Scholar
• Vincent SH, Reed JR, Bergman AJ, et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C] sitagliptin in humans. Drug Metab Dispos 2007;35:533-8
   PubMed Web of Science ®Google Scholar
• Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 2008;25:1229-30
   PubMed Web of Science ®Google Scholar
• Mistry GC, Bergman AJ, Zheng W, et al. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol 2008;66:36-42
   PubMed Web of Science ®Google Scholar
• Mistry GC, Bergman AJ, Luo WL, et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol 2007;47:159-64
   PubMed Web of Science ®Google Scholar
• Herman GA, Bergman A, Yi B, Kipnes M; The Sitagliptin Study 012 Group. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 2006;22:1939-347
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Sitagliptin. Drugs 2007;67:587-97
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Feinglos MN, Lunceford JK, et al; for the Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87
   PubMed Web of Science ®Google Scholar
• Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24:537-50
   PubMed Web of Science ®Google Scholar
• Mistry GC, Bergman AJ, Zheng W, et al. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol 2008;66:36-42
   PubMed Web of Science ®Google Scholar
• Mistry GC, Bergman AJ, Luo WL, et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol 2007;47:159-64
   PubMed Web of Science ®Google Scholar
• Chu XY, Bleasby K, Yabut J, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transpoter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007;321:673-83
   PubMed Web of Science ®Google Scholar
• He YL, Sabo R, Wang Y, et al. The influence of age, gender and BMI on the pharmacokinetics and pharmacodynemics of vildagliptine. Clin Pharmacol Ther 2006;79:63
   Web of Science ®Google Scholar
• Hu P, Yin Q, Deckert F, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol 2009;49:39-49
   PubMed Web of Science ®Google Scholar
• He YL, Sabo R, Picard F, et al. Lack of pharmacokinetic interaction between vildagliptin and metformin in patients with type 2 diabetes. Clin Pharmacol Ther 2006;79:62
   PubMed Web of Science ®Google Scholar
• Barilla D, He Y, Balez S, et al. No pharmacokinetic interactions or acute clinical safety issues preclude combination of the DPP-4 inhibitor LAF237 with glyburide. Diabetes 2004;53(Suppl 2):470
   Google Scholar
• Serra DB, He YL, Wang Y, et al. Combination of the DPP-4 inhibitor vildagliptin (LAF237) with pioglitazone is safe and well toleratedwith no pharmacokinetic interaction. Diabetes 2005;54(Suppl 1):528-9
   Google Scholar
• Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008;10:1047-53
   PubMed Web of Science ®Google Scholar
• Serra D, He YL, Bullock J, et al. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. Int J Clin Pharmacol Ther 2008;46:349-64
   PubMed Web of Science ®Google Scholar
• Fonseca V, Schweizer A, Albrect D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-55
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula SP, Dole K, He YL, et al. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 2007;23:2913-20
   PubMed Web of Science ®Google Scholar
• He YL, Ligueros-Saylan M, Sunkara G, et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol 2008;48:85-95
   PubMed Web of Science ®Google Scholar
• He YL, Sabo R, Sunkara G, et al. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol 2007;47:998-1004
   PubMed Web of Science ®Google Scholar
• He YL, Sabo R, Riviere GJ, et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin 2007;23:1131-8
   PubMed Web of Science ®Google Scholar
• He YL, Flannery B, Campestrini J, et al. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. Curr Med Res Opin 2008;24:1703-9
   PubMed Web of Science ®Google Scholar
• He YL, Sabo R, Campestrini J, et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol 2007;63:677-86
   PubMed Web of Science ®Google Scholar
• Donnelly LA, Doney AS, Morris AD, et al. Long-term adherence to statin treatment in diabetes. Diabet Med 2008;25:850-5
   PubMed Web of Science ®Google Scholar